Furthermore, inhibition of pro-lymphangiogenic factors, such as VEGF-C, VEGF-D, NRP2 and VEGFR3, prior to disease spread can reduce the occurrence of metastatic lesions within SLNs [20], [28], [32]–[35], suggesting that antagonism of this pathway may provide an approach to mitigate metastatic disease. This evidence concerns the gene NRP2 and metastatic neoplasm.